Is Natera, Inc. (NTRA) a Buy, Sell, or Hold?
NASDAQ : NTRA
Natera, Inc.
$277.4 USD
$0.03 (0.01%)
- Volume
- 193.12K
- Average Volume
- 1.57M
- Market Capitalization
- $39.73B
- P/E Ratio
- -170.18
- Dividend Yield
- 0.00%
- Price Target
- $275.00
- Year High
- $288.04
- Year Low
- $131.81
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.96
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Steven Leonard Chapman |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Current Symbol | NTRA |
| CUSIP | 632307104 |
| CIK | 0001604821 |
| Web | https://www.natera.com |
| Phone | 650 249 9090 |
| Currency | USD |
| Employees | 6140 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.14 |
| Payout Ratio | 0.00 |
| Current Ratio | 2.96 |
| Quick Ratio | 2.83 |
| Cash Ratio | 1.95 |
Sales & Book Value
| Annual Sales | $2.31B |
| Price / Sales | 15.89 |
| Cash Flow | 0.65 |
| Price / Cash Flow | 431.78 |
| Price / Book | 22.13 |
Price Target and Rating
| Average Stock Price Forecast | $275.00 |
| High Stock Price Forecast | $330.00 |
| Low Stock Price Forecast | $220.00 |
| Forecast Upside/Downside | 0.87% |
| Consensus Rating | Strong Sell |
| Rating Score(0-5) | 1 |
| Research Coverage | 27 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | -$1.52 |
| Trailing P/E Ratio | -170.18 |
| PEG Ratio | 5.65 |
| P/E Growth | 5.65 |
| Net Income | -$208.16M |
| Net Margin | -9.05% |
| Pretax Margin | -11.44% |
| Return on Equity | -15.13% |
| Return on Assets | -8.66% |
Financials Score
| AltmanZ Score | 28.17 |
| Piotroski Score | 4.00 |
| Working Capital | 1.09B |
| Total Assets | 2.61B |
| Ebit | -277.8M |
| Market Cap | 40.05B |
| Total Liabilities | 840.38M |
Poll Results
About Natera, Inc. (NASDAQ:NTRA) Stock
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help under ... stand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
2026-07-16 08:00:00
It may not be a familiar name, but Natera has provided better returns than Nvidia over the past 12 months.
NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers
2026-07-10 11:01:08
Natera's Signatera became the first personalized MRD test for solid tumors to earn EU IVDR certification, supporting broader expansion across Europe.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
2026-07-09 09:56:07
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers
2026-07-09 06:00:00
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that Signatera has received certification as a Class C device under the European Union's In Vitro Diagnostic Regulation (IVDR). The IVDR represents one of the world's most rigorous regulatory frameworks for in vitro diagnostic medical devices, replacing the outgoing In Vitro Diagnostic Medical Devices Directive (IVDD). To obtain certification, the Signatera platf.
2026-07-06 06:00:00
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in JAMA Oncology, evaluating the utility of Signatera, its personalized molecular residual disease (MRD) test, in patients with resected colorectal liver metastases (CRLM). The data was also presented as an oral presentation at the 2026 European Society for Medical Oncology Gastrointestinal (ESMO GI) Congress. The liver is the most com.
NTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck Cancer
2026-07-01 12:01:10
Natera's Aveta partnership brings Signatera into a global Phase 3 head and neck cancer trial to assess MRD and treatment response.
Natera, Aveta partner on late-stage head and neck cancer trial
2026-06-29 06:55:52
Genetic testing firm Natera and cancer drug developer Aveta Biomics said on Monday they have partnered on a late-stage study of an experimental therapy for head and neck cancer, in a bid to improve how patients' response to treatment is monitored.
2026-06-29 06:00:00
AUSTIN, Texas & BEDFORD, Mass.--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, and Aveta Biomics, Inc., a clinical-stage immuno-oncology company advancing first-in-class oral immunotherapies for solid tumors, today announced a strategic partnership supporting AVTA 30-01, Aveta's global Phase 3 registrational clinical trial evaluating APG-157 in patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC) (NCT07667296).APG.
Frequently Asked Questions
-
What is the current Natera, Inc. (NTRA) stock price?
-
Natera, Inc.(NASDAQ:NTRA) stock price is $277.4 in the last trading session. During the trading session, NTRA stock reached the peak price of $288.04 while $131.811 was the lowest point it dropped to. The percentage change in NTRA stock occurred in the recent session was 0.01% while the dollar amount for the price change in NTRA stock was $0.03.
-
NTRA's industry and sector of operation?
-
The NASDAQ listed NTRA is part of Medical - Diagnostics & Research industry that operates in the broader Healthcare sector.
-
Who are the executives of NTRA?
-
Michael Brophy | Chief Financial Officer
Solomon Moshkevich | President of Clinical Diagnostics
Matthew Rabinowitz | Co-Founder & Executive Chairman
John Fesko | President & Chief Business Officer
Steven Leonard Chapman | Chief Executive Officer & Director -
How many employees does NTRA have?
-
Number of NTRA employees currently stands at 6140. NTRA operates from 13011 McCallen Pass Building A, Austin, TX 78753, US.
-
Link for NTRA official website?
-
Official Website of NTRA is: https://www.natera.com
-
How do I contact NTRA?
-
NTRA could be contacted at phone #650 249 9090 and can also be accessed through its website. NTRA operates from 13011 McCallen Pass Building A, Austin, TX 78753, US.
-
How many shares of NTRA are traded daily?
-
The average number of NTRA shares traded daily for last 3 months was 1.57M.
-
What is the market cap of NTRA currently?
-
The market value of NTRA currently stands at $39.73B with its latest stock price at $277.4